#EULAR2022 Prof Pascual gave a great talks on use of transcriptomic analysis in stratifying #lupus & disease understanding. Tour de force from blood IFN signature use to Plasmablast (correlate with activity inc. in African) and Neutrophil/myeloid signatures (nephritis) @RheumNow https://t.co/tiX55ARDvC

Prof T Dorner summarizes what's new in #SLE #EULAR2022 @rheumnow https://t.co/YT0Ocw7I41

Interestingly, anti-IFN Ab can be present in #SLE pts and impact the IFN signature. There is a bimodal type I IFN signature in #SLE. IFN and Blys signatures overlap (?distinct populations/interactions between the two?) - Prof T Dorner #EULAR2022 @rheumnow https://t.co/phLXv2KVxR

#OP0142 #EULAR2022 Morand compared LLDAS in Early (<1yr) and Established #lupus. Although Early were younger & had higher disease activity, time-to-LLDAS was shorter. LLDAS was protective of flare in both. Should target for LLDAS early in diagnosis to improve outcomes @RheumNow https://t.co/7i9c69YkR3

In people without SLE who have severe COVID19 infection, autoAb against IFN-1 assc w/increased mortality Prof T Dorner #EULAR2022 @rheumnow https://t.co/nt2gACUtkL

New #SLE drug to pay attention to! iberdomide target Ikaros and Aiolos, reduce B cell, reduce autoAb and reduce IFN sig while enhancing regulatory T cells- Prof T Dorner #EULAR2022 @rheumnow https://t.co/q39pxK3gFJ

#ClinicalPearl #SLE Rx tomorrow? Combine #Ritux+#Belimumab variable response, CART Rx for severe refractory #lupus, antiCD38i, drugs i. RCTs=hope for pts. #EULAR2022 T Dorner @RheumNow @eular_org https://t.co/2BReU5bhG0

No need to switch TNFi during pregnancy. Study compared high placental vs. low placental transfer TNFi- no sig difference for SIE in childhood. Dr. L Flatman comparing different TNFi in pregnancy: 26,000 offsprings #EULAR2022 @rheumnow OP0130 https://t.co/IF5hepQoHc

#SLE hospitalized pts had worse outcomes than matched controls ? Due to interfonopathy and poor handling of viral infections - worse if #Rituximab or #MMF T Dormer BUT vaccination works if enough B cells responding to #Covid vaccine #EULAR2022 #Lupus scientific session @RheumNow https://t.co/MBb3Dvxmqp

Million $$$ questions presented to Prof T Dorner: anifrolumab vs. belimumab for #SLE? He prefers belimumab d/t more data on multiple organ manifestations ^ it might be protective in pts w/ COVID19 infection. If skin dz is predominant, then anifrolumab #EULAR2022 @rheumnow